Posted by Michael Wonder on 16 Jul 2025
MHRA approves sebetralstat (Ekterly) to treat hereditary angioedema attacks in patients aged 12 and over
15 July 2025 - The MHRA has today approved sebetralstat (Ekterly) for the treatment of hereditary angioedema attacks in adults and adolescents aged 12 years and older.
Sebetralstat’s approval is supported by the KONFIDENT clinical trial, in which 110 patients experienced and treated 264 hereditary angioedema attacks.
